Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Open-label Study of Adjuvant CUE-102, a WT-1-pHLA-IL2-Fc Fusion Protein in Glioblastoma (GBM) Patients at First Recurrence

NCT06917885 is registered in ClinicalTrials.gov with David Reardon, MD as lead sponsor.

NCT NCT06917885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Open-label Study of Adjuvant CUE-102, a WT-1-pHLA-IL2-Fc Fusion Protein in Glioblastoma (GBM) Patients at First Recurrence
Lead sponsor
David Reardon, MD
Phase
Phase 1
Overall status
Recruiting
Start date
July 30, 2025
Completion date
January 31, 2028
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioma, malignant, recurrent glioblastoma